Relapse after cessation of weekly tocilizumab for giant cell arteritis: a multicentre service evaluation in England

<p><strong>Objectives</strong> The National Health Service in England funds 12 months of weekly s.c. tocilizumab (qwTCZ) for patients with relapsing or refractory GCA. During the coronavirus disease 2019 (COVID-19) pandemic, some patients were allowed longer treatment. We sought to...

Full description

Bibliographic Details
Main Authors:	Quick, V, Abusalameh, M, Ahmed, S, Alkoky, H, Bukhari, M, Carter, S, Coath, FL, Davidson, B, Doddamani, P, Dubey, S, Ducker, G, Griffiths, B, Gullick, N, Heaney, J, Holloway, A, Htut, EEP, Hughes, M, Irvine, H, Kinder, A, Kurshid, A, Lim, J, Ludwig, DR, Malik, M, Mercer, L, Mulhearn, B, Nair, JR, Patel, R, Robson, J, Saha, P, Tansley, S, TOC STOP 2022 Investigators, Mackie, SL
Format:	Journal article
Language:	English
Published:	Oxford University Press 2023

Relapse after cessation of weekly tocilizumab for giant cell arteritis: a multicentre service evaluation in England

Similar Items